Showing results (211-220 of 249) with videos related to
Sort By:
Pageof 25
Cancer Medicine|June 6, 2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinomaLetizia Procaccio, Valeria Merz, Morena Fasano, et al.Tumori|December 24, 2016
Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care)Vittorina Zagonel, Vittorio Franciosi, Antonella Brunello, et al.Cancers|February 25, 2022
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal AntibodiesAnna Maria Rachiglio, Laura Forgione, Raffaella Pasquale, et al.British Journal of Cancer|May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2019
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance TherapyFederica Morano, Salvatore Corallo, Sara Lonardi, et al.The New England Journal of Medicine|May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancerRobert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.Future Oncology (London, England)|May 31, 2018
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRCCarmine Pinto, Nicola Normanno, Armando Orlandi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE StudyVeronica Conca, Daniele Rossini, Carlotta Antoniotti, et al.European Journal of Cancer (Oxford, England : 1990)|December 15, 2020
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancerPaolo Manca, Salvatore Corallo, Giovanni Randon, et al.Pageof 25